The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Open accessAbstract
Objective: Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. No drug to date targets both systemic inflammatory disease and the cardiovascular complications of SLE. Tofacitinib is a JAK inhibitor that blocks signaling downstream of multiple cytokines implicated in lupus pathogenesis. While clinical trials have shown that tofacitinib exhibits significant clinical efficacy in various autoimmune diseases, its role in SLE and the associated vascular pathology remains to be characterized. Methods: MRL/lpr lupus‐prone mice were administered tofacitinib or vehicle by gavage for 6 weeks (therapeutic arm) or 8 weeks (preventive arm). Nephritis, skin inflammation, serum levels of autoantibodies and cytokines, mononuclear cell phenotype and gene expression, neutrophil extracellular traps (NETs) release, endothelium‐dependent vasorelaxation, and endothelial differentiation were compared in treated and untreated mice. Results: Treatment with tofacitinib led to significant improvement in measures of disease activity, including nephritis, skin inflammation, and autoantibody production. In addition, tofacitinib treatment reduced serum levels of proinflammatory cytokines and interferon responses in splenocytes and kidney tissue. Tofacitinib also modulated the formation of NETs and significantly increased endothelium‐dependent vasorelaxation and endothelial differentiation. The drug was effective in both preventive and therapeutic strategies. Conclusion: Tofacitinib modulates the innate and adaptive immune responses, ameliorates murine lupus, and improves vascular function. These results indicate that JAK inhibitors have the potential to be beneficial in SLE and its associated vascular damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells
Lighvani, A. A., Frucht, D. M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B. D., Nguyen, B. V., Gadina, M., Sher, A., Paul, W. E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261570598 · Cited by 783 · cited 1×
“In particular, type I IFN–driven ISGs (Mx-1, STAT-1, ISG-15, and IFIT-1) were the most significantly reduced (Figure 5D) (37,38).”
BackgroundSelf-citationKnight, J. S., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Zhao, W., Smith, C. K., Hodgin, J. B., Thompson, P. R., & Kaplan, M. J. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205365 · Cited by 443
Self-citation
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Self-citationBanerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Self-citationThe role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review
Lee, K. H., Kronbichler, A., Park, D. D.-Y., Park, Y., Moon, H., Kim, H., Choi, J. H., Choi, Y., Shim, S., Lyu, I. S., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.012 · Cited by 624
Metadata
- Authors
- Furumoto, Y., Smith, C. K., Blanco, L., Zhao, W., Brooks, S. R., Thacker, S. G., Zarzour, A., Sciumè, G., Tsai, W. L., Trier, A. M., Nunez, L., Mast, L., Hoffmann, V., Remaley, A. T., O'Shea, J. J., Kaplan, M. J., & Gadina, M.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2016-12-28
- Volume
- 69
- Issue
- 1
- Pages
- 148-160
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2504534335
- Cited by
- 217
- References
- 2
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. https://app.cochat.ai/papers/10.1002/art.39818
- The paper
- Furumoto, Y., Smith, C. K., Blanco, L., Zhao, W., Brooks, S. R., Thacker, S. G., Zarzour, A., Sciumè, G., Tsai, W. L., Trier, A. M., Nunez, L., Mast, L., Hoffmann, V., Remaley, A. T., O'Shea, J. J., Kaplan, M. J., & Gadina, M. (2017). Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis & Rheumatology. https://doi.org/10.1002/art.39818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.